United States: Fireworks For Animal Drug Compounding At ACI's Inaugural Animal Health And Veterinary Drugs And Therapeutics Conference-Part Two Of Two

Last Updated: October 1 2015
Article by Brian J. Malkin

Here continues Part Two of our coverage of the American Conference Institute (ACI's) inaugural Legal, Regulatory and Compliance Forum on Animal Health and Veterinary Drugs and Therapeutics Conference held in New York City on September 10-11, 2015. For Part One, see here.

The second day began with a deep dive into the development of advanced biological drugs for animal use. David Brake, Ph.D., Founder and Principal, BioQuest Associates, LLC, helped explain the split between USDA and FDA regulating biologics, which have confounded many in the industry. USDA's Center for Veterinary Biologics (CVB) generally regulates biologics with an immunological process for treating disease, e.g., antibodies, immunomodulators, and immunostimulants. FDA's Center for Veterinary Medicines (CVM), on the other hand, regulates certain veterinary vaccines and biologics, where the mechanism of action is not immunological, e.g., monoclonal antibodies that control pain or have other nonimmunological functions, recombinant proteins, gene and stem cell therapies, cytokines, and interferons. This agency split of authority is explained in a USDA-FDA Memorandum of Understanding. Some examples of USDA CVB's licensed products include monoclonal antibodies developed by Aratana Therapeutics ("Aratana") to treat canine lymphoma, and Merial's Oncept®, which uses DNA and recombinant bacteria vaccines to treat animal cancers and predates similar products for humans. FDA's CVM includes cyotokines, certain monoclonal antibodies, e.g., Nexvet Biopharma's (Nexvet's) monoclonal antibody to control pain associated with neurodegenerative diseases in dogs or cats, and Nexvet's recombinant proteins to treat canine inflammatory diseases, such as atopic dermatitis, or Aratana's stem cell therapy Regeneus Cryoshot® Canine to treat canine osteoarthritis. Brake opined that many industry members believe it is better to be regulated by USDA's CVB rather than FDA's CVM, because there are generally lower research and development costs and eased manufacturing guidelines—both leading to faster regulatory approval times with continuous submission reviews. Natasha Leskovsek, Partner, Cooley LLP, then provided additional input regarding post-approval concerns, such as immunogenicity, which has also been seen with biosimilars.

In a post-discussion question by Brian Malkin, Senior Counsel, McGuireWoods LLP, on petitioning for changing from FDA to USDA or vice versa, McClure suggested that companies may use their labeling claims and intended use to help direct their biological veterinary products to FDA or USDA, depending on the perceived mechanism of action. Linda Rhodes, VMD, Ph.D., Chief Scientific Officer, Aratana, who co-chaired the afternoon's post-conference workshop, provided an example where an immunocontraceptive for deer initially appeared to be regulated by FDA, which was petitioned later to be reviewed by the EPA as the more appropriate agency. This case suggests that companies may have an impact in determining the reviewing agency for new product categories, which is an important product development issue. And yet other attendees noted confusing examples where seemingly similar biological classes of products were either regulated by FDA or USDA without apparent clear lines regarding immunological action, further indicating that companies should stay on top of this issue.

Next, the topic turned to advertising and promotion for animal medicines. Jennifer Harmer, Director, Regulatory Affairs North America (Pharmaceuticals), Merial, Inc., explained the challenges of complying with three different regulatory bodies for approval and labeling (FDA, USDA, and EPA) along with one general advertising enforcer (FTC) with several private enforcement mechanisms, including the National Advertising Division (NAD) and Lanham Act Litigations. For example, only FDA requires promotional materials at time of promotion and only EPA requires pre-approval of all promotional claims, and the FTC focuses specifically on deceptive advertising. NAD is a private, self-regulatory group that investigates advertising and gives advertisers a mechanism for resolving disputes voluntarily, which is faster than the litigation route via the Lanham Act. While the Amarin decision is interesting (see related blog here), Harmer cautioned to "not go overboard with it," because FDA likely views it as an unusual case and not many animal health companies appear to be engaging in offlabel claims.

The main conference then concluded with discussions on good manufacturing practices (cGMPs), adverse event reporting, and class action lawsuits in the animal drug industry. As with the other presentations, the complexity of dealing with products regulated by FDA, USDA, or EPA plays in these activities. Given the success of the program, ACI indicated that the program was likely to be continued next year.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions